Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia

被引:102
作者
Daskalopoulou, SS
Tzovaras, V
Mikhailidis, DP
Elisaf, M [1 ]
机构
[1] Univ Ioannina, Sch Med, Dept Internal Med, GR-45110 Ioannina, Greece
[2] Univ London, Royal Free & Univ Coll Med Sch, Royal Free Hosp, Dept Clin Biochem, London, England
关键词
uric acid; urate; uricosuric; fenofibrate; losartan; NSAID; diuretic; atorvastatin;
D O I
10.2174/138161205774913309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Beyond allopurinol and the well-established uricosuric drugs, several other agents can decrease serum uric acid (SUA) levels, such as losartan, fenofibrate and some non-steroidal anti-inflammatory drugs (NSAIDs). Some of these drugs increase renal urate excretion. Hyperuricaemia and gout are common problems (at least 1% of Western men are affected by gout). Raised SUA levels increase the incidence of acute gout and renal calculi. Hyperuricaemia may also predict an increased risk of vascular events. Therefore, lowering SUA levels is of clinical relevance. In this review we consider the effect on SUA levels of drugs that are prescribed for indications other than treating hyperuricaemia. These drugs may obviate the need for specific treatment (e.g. allopurinol) aimed at lowering SUA levels. Furthermore, because hyperuricaemic patients may already be on several drugs (e.g. due to associated dyslipidaemia, hypertension and/or arthritis) compliance may be improved by avoiding additional medication. The potential for adverse effects associated with polypharmacy would also be decreased.
引用
收藏
页码:4161 / 4175
页数:15
相关论文
共 285 条
[91]   Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists in experimental myocarditis [J].
Godsel, LM ;
Leon, JS ;
Engman, DM .
CURRENT PHARMACEUTICAL DESIGN, 2003, 9 (09) :723-735
[92]   Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity [J].
Gokcel, A ;
Gumurdulu, Y ;
Karakose, H ;
Ertorer, EM ;
Tanaci, N ;
Tutuncu, NB ;
Guvener, N .
DIABETES OBESITY & METABOLISM, 2002, 4 (01) :49-55
[93]   Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control [J].
Gokcel, A ;
Karakose, H ;
Ertorer, EM ;
Tanaci, N ;
Tutuncu, NB ;
Guvener, N .
DIABETES CARE, 2001, 24 (11) :1957-1960
[94]   EFFECTS OF PROBENECID ON THE PHARMACOKINETICS AND PHARMACODYNAMICS OF ADINAZOLAM IN HUMANS [J].
GOLDEN, PL ;
WARNER, PE ;
FLEISHAKER, JC ;
JEWELL, RC ;
MILLIKIN, S ;
LYON, J ;
BROUWER, KLR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 56 (02) :133-141
[95]   THE URICOSURIC EFFECT OF OXAPROZIN IN HUMANS [J].
GOLDFARB, S ;
WALKER, BR ;
AGUS, ZS .
JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 25 (02) :144-148
[96]   ENALAPRIL - A REVIEW OF HUMAN PHARMACOLOGY [J].
GOMEZ, HJ ;
CIRILLO, VJ ;
IRVIN, JD .
DRUGS, 1985, 30 :13-24
[97]  
González-Ortiz M, 2000, J NEPHROL, V13, P126
[98]  
GOSTICK NK, 1989, J HUM HYPERTENS, V3, P141
[99]   BLOOD DYSCRASIA ASSOCIATED WITH AZAPROPAZONE THERAPY [J].
GREEN, ST ;
MCMILLAN, H ;
ERWIN, L .
ANNALS OF THE RHEUMATIC DISEASES, 1985, 44 (04) :286-286
[100]  
Gregorio F, 1996, DIABETES METAB, V22, P43